CXCR3

CXCR3

CXCR3 Molekülinformation

Molecule Name
C-X-C motif chemokine receptor 3
Molekülalias
CD182, CD183, CKR-L2, CMKAR3, GPR9, IP10-R, Mig-R, MigR
Drug Development Progress
Anzahl der klinischen Arzneimittel2
Anzahl der inverkehr gebrachten Arzneimittel0
Höchste Forschungs- und EntwicklungsphasePhase 1 Clinical
Target-Alias
CKR-L2,G protein-coupled receptor 9,IP-10 receptor,CXCR-3,CXC-R3,CXCR3,C-X-C Motif Chemokine Receptor 3,Interferon-Inducible Protein 10 Receptor,GPR9,C-X-C Chemokine Receptor Type 3,Chemokine Receptor 3,CD183 Antigen,CMKAR3,Chemokine (C-X-C Motif) Receptor 3,Mig Receptor,IP10-R,CD182,CD183,Mig-R,MigR,Receptors, CXCR3
Molekülhintergrund
Chemokines are proteins which induce chemotaxis, promote differentiation of immune cells, and cause tissue extravasation. Given these properties, their role in anti-tumor immune response in the cancer environment is of great interest. Although immunotherapy has shown clinical benefit for some cancer patients, other patients do not respond. One of the mechanisms of resistance to checkpoint inhibitors may be chemokine signaling. The CXCL9, -10, -11/CXCR3 axis regulates immune cell migration, differentiation, and activation, leading to tumor suppression (paracrine axis). However, there are some reports that show involvements of this axis in tumor growth and metastasis (autocrine axis). Thus, a better understanding of CXCL9, -10, -11/CXCR3 axis is necessary to develop effective cancer control.

CXCR3 Produktliste

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
OCU-110OCU-10-C-110; OGX-110; OCU-110Phase 1 ClinicalOcugenix Corp
Macular Degeneration
Details
ACT-777991ACT-777991Phase 1 ClinicalIdorsia Pharmaceuticals Ltd
Diabetes Mellitus, Type 1; Inflammation
Details